Dermatology and Autoimmune Skin Disease Research
At Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico in Milan, clinical trials in Dermatology focus on inflammatory and autoimmune skin conditions, with an emphasis on improving symptom control and long-term disease management.
- Cutaneous lupus erythematosus and chronic skin inflammation
- Alopecia areata and treatment response in severe hair loss
- Studies of litifilimab and upadacitinib for better disease control and safety
These trials aim to test new therapies and evaluate whether they can offer more effective and better-tolerated options for people living with persistent autoimmune skin disease.
Cardiovascular and Thromboembolic Prevention
The site is also active in Cardiovascular Diseases, with research directed toward preventing major heart and circulation events and refining treatment strategies for people at elevated risk.
- Atrial fibrillation and prevention of stroke-related complications
- Acute coronary syndrome and broader cardiovascular risk reduction
- Trials of inclisiran and milvexian to assess effectiveness and safety
These studies are designed to improve prevention of serious cardiovascular outcomes and support more reliable long-term risk reduction.
Gastroenterology and Liver Disease
Clinical research in Digestive System Diseases and Nutritional and Metabolic Diseases includes conditions affecting the liver and intestines, with a strong focus on therapies that may reduce inflammation and improve disease symptoms.
- Non-alcoholic steatohepatitis and liver fibrosis
- Crohn’s disease and inflammatory bowel disease control
- Primary biliary cholangitis with treatment of persistent itching
These trials are evaluating whether new treatments can improve liver health, ease gastrointestinal inflammation, and relieve burdensome symptoms such as pruritus.
Neurology and Neurodegenerative Disease
Research in Nervous System Diseases at this hospital includes studies of progressive brain disorders, with the goal of understanding whether emerging treatments can slow decline or improve cognitive and motor outcomes.
- Alzheimer’s disease and related dementia
- Parkinson’s disease with a genetic subtype linked to GBA1
- Evaluation of therapies such as ABBV-916, MK-1942, and BIA 28-6156
These studies focus on testing new approaches for slowing disease progression, supporting cognition, and improving daily functioning.
Hematology and Blood Cancer Studies
In Neoplasms and blood-related disorders, the research portfolio includes cancers and hematologic diseases where investigators are assessing whether newer treatments can improve disease control and patient outcomes.
- Diffuse large B-cell lymphoma and other aggressive lymphomas
- Chronic lymphocytic leukemia and myelofibrosis
- Paroxysmal nocturnal hemoglobinuria and warm autoimmune hemolytic anemia
These trials are designed to examine treatment effectiveness, safety, and the potential for more durable disease control in complex hematologic conditions.
Respiratory, Transplant, and Infectious Disease Research
The site also contributes to studies in Respiratory Tract Diseases, Bacterial Infections and Mycoses, and Virus Diseases, including research in transplant-related illness and hard-to-treat infections.
- Bronchiectasis and cystic fibrosis bronchiectasis
- Lung transplant rejection and chronic lung allograft dysfunction
- Candidemia, invasive candidiasis, and respiratory syncytial virus prevention
These trials aim to improve infection treatment, support transplant health, and evaluate vaccines and therapies that may reduce complications in vulnerable patients.
Ophthalmology and Vision Preservation
Clinical trials in Eye Diseases are exploring ways to protect vision and slow retinal damage, with a focus on conditions that can gradually impair sight.
- Geographic atrophy linked to age-related macular degeneration
- Macular edema secondary to retinal vein occlusion
- Studies assessing visual outcomes and retinal disease control with new therapies
These investigations are intended to improve eye health by testing whether emerging treatments can preserve visual function and limit progression of retinal disease.
